SEATTLE, Sept. 6, 2013 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) today
announced the appointment of Ted W. Love, M.D., to its board of
"We are pleased to welcome Dr. Love, with his extensive experience in
drug development, operations and corporate governance, to our board of
directors," said Robert L. Kirkman, M.D., President and Chief Executive
Officer of Oncothyreon.
Dr. Love served as Executive Vice President and Head of Research and
Development and Technical Operations at Onyx Pharmaceuticals, Inc.,
from February 2010 to August 2012. From 2001 to January 2009, Dr. Love
served as Chairman and Chief Executive Officer of Nuvelo, Inc. Dr. Love
joined Nuvelo from Theravance, Inc., where he served as Senior Vice
President of Development from 1998 to 2001. Previously, he spent six
years at Genentech, Inc., where he held a number of senior management
positions in medical affairs and product development and served as
chairman of Genentech's Product Development Committee. Dr. Love also
serves as a member of the boards of directors of biopharmaceutical
companies Santarus, Inc., Amicus, Inc., and Kalobios, Inc. Until April
2012, he served on the California Independent Citizens' Oversight
Committee. Dr. Love earned his Bachelor of Science in molecular biology
from Haverford College and his M.D. from Yale Medical School.
Oncothyreon is a biotechnology company specializing in the development
of innovative therapeutic products for the treatment of cancer.
Oncothyreon's goal is to develop and commercialize novel synthetic
vaccines and targeted small molecules that have the potential to
improve the lives and outcomes of cancer patients. For more
information, visit www.oncothyreon.com.
Additional information relating to Oncothyreon can be found on EDGAR at www.sec.gov and on SEDAR at www.sedar.com.
SOURCE Oncothyreon Inc.